Cost-efficacy of individual and combined treatments for panic disorder

Journal of Clinical Psychiatry

Volumn 68, Issue 7, 2007, Pages 1038-1044

  McHugh, R Kathryn ^a   Otto, Michael W ^a   Barlow, David H ^a   Gorman, Jack M ^b   Shear, M Katherine ^c   Woods, Scott W ^d  

^a BOSTON UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PAROXETINE;

ARTICLE; CALCULATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; EMPIRICISM; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PANIC; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOCIAL PSYCHOLOGY;

EID: 34548311567     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0710     Document Type: Article

References (34)

1. White KS, Barlow DH. Panic disorder and agoraphobia. In: Barlow DH, ed. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York, NY: The Guilford Press; 2002
2. Hofmann SG, Barlow DH. The costs of anxiety disorders: implications for psychosocial interventions. In: Miller NE, Magruder KM, eds. Cost-Effectiveness of Psychotherapy: A Guide for Practitioners, Researchers, and Policymakers. New York, NY: Oxford University Press; 1999
3. Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 2005;21:178-184
4. Addis ME, Hatgis C, Krasnow AD, et al. Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting. J Consult Clin Psychol 2004;72:625-635
5. Craske MG, Brown TA, Barlow DH. Behavioral treatment of panic disorder: a two-year follow-up. Behav Ther 1991;22:289-304
6. Kenardy J, Robinson S, Dob R. Cognitive behaviour therapy for panic disorder: long-term follow-up. Cogn Behav Ther 2005;34:75-78
7. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
8. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Review 1995;15:819-844
9. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry 1993;162:776-787
10. Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149:1053-1057
11. Craske MG, Golinelli D, Stein MB, et al. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting? Psychol Med 2005;35:1645-1654
12. Furukawa TA, Wantanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry 2006;188:305-312
13. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005;62:290-298
14. Katon WJ, Roy-Byrne P, Russo J, et al. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry 2002;59:1098-1104
15. Mavissakalian MR, Schmier JK, Flynn JA, et al. Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. Pharmacoeconomics 2000;18:383-391
16. Otto MW, Pollack MH, Maki KM. Empirically-supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol 2000;68:556-563
17. Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004;38:602-612
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Barlow DH, Gorman JM, Shear MK, et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283:2529-2536
20. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder. Arlington, Va: American Psychiatric Association; 1998
21. Bakker A, van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 2005;8:473-482
22. Otto MW, Tuby KS, Gould RA, et al. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001;158:1989-1992
23. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative Panic Disorder Severity Scale. Am J Psychiatry 1997;154:1571-1575
24. Shear MK, Rucci P, Williams J, et al. Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res 2001;35:293-296
25. Otto MW, Pollack MH, Penava SJ. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther 1999;37:763-770
26. Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:678
27. Marchesi C, Cantoni A, Fonto S, et al. Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study. Pharmacopsychiatry 2006;39:60-65
28. Fleming T, ed. Drug Topics Red Book. Montvale, NJ: Thomson PDR; 2005
29. Centers for Medicare and Medicaid Services. National Physician Fee Schedule and Relative Value Files. Available at: http://www.cms.hhs.gov/apps/ pfslookup/display.asp. Accessed May 21, 2006
30. Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998;155:43-47
31. Marks IM, Lelliott P, Basolgu M, et al. Clomipramine, self-exposure, and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988;152:522-534
32. Katon W, Russo J, Sherbourne C, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med 2006;36:353-363
33. Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behav Ther 1997;28:187-210
34. Drummond MF, Stoddard GL, Torrance GW. Methods for the Economic Evaluation of Health Care. Oxford, England: Oxford University Press; 1987